PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): M&A transaction — PacBio completes sale of short-read sequencing assets to Illumina for $48.1M net cash

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Sold certain short-read DNA sequencing IP and related technologies to Illumina for $50M gross; net cash proceeds $48.1M.
Illumina assumed certain liabilities and granted PacBio a non-exclusive license back to certain IP.
Transaction closed Jan 30, 2026; company to focus on long-read sequencing and accelerate SPRQ-Nx chemistry launch.
Proceeds strengthen balance sheet; $1.9M paid to former Apton equity holders to waive milestone obligations.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. completed a disposition involving Illumina Cambridge Limited for $50.0 million in cash (closed 2026-01-30).

Action: disposition
Counterparty: Illumina Cambridge Limited
Consideration: $50.0 million in cash
Closing: 2026-01-30

Exact text from the filing

On January 30, 2026, Pacific Biosciences of California, Inc. (the “Company”) completed the disposition of assets to Illumina Cambridge Limited (the “Buyer”) in accordance with the terms of an Asset Purchase Agreement, dated January 30, 2026 (the “Asset Purchase Agreement”), by and between the Company, the Buyer, and Illumina, Inc., solely for purposes of Section 8.16 of the Asset Purchase Agreement, pursuant to which, among other matters, the Buyer acquired certain intellectual property and other assets related to the Company’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies (the “Asset Sale”). As consideration for the Asset Sale, the Buyer paid the Company $50.0 million in cash and assumed certain liabilities (the “Purchase Price”).

View on SEC.gov

Browse all m&a transactions →

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-009014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.